Inflammation, Brain
7
1
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment
Predictive BioMArkers of AlTERed NeurologicAL Trajectories Consequent to PrenataL InflammatorY Insults
Dysautonomia and Systemic Interactions in Traumatic Brain Injury
Efficacy Evaluation of the Mushroom Beverage on Emotion Regulation
Control of Leukocyte Function
PRIME: Cognitive Outcome Following Major Burns